SFSIG
CTMX icon

San Francisco Sentry Investment Group’s CytomX Therapeutics CTMX Stock Holding History

San Francisco Sentry Investment Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-80
Closed -$1K – 910
2019
Q2 		$1K Buy
+80
New +$839 ﹤0.01% 815

Other funds holding CTMX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

San Francisco Sentry Investment Group's CTMX Position: Q3 2019 in Review

San Francisco Sentry Investment Group sold out of CytomX Therapeutics (CTMX) in Q3 2019, closing a stake of 80 shares — an estimated $1K sold.

San Francisco Sentry Investment Group first reported a position in CTMX in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 113 funds tracked by Wall St. Rank hold CTMX as of Q3 2019.

  • San Francisco Sentry Investment Group reported no remaining CytomX Therapeutics position as of Q3 2019 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 80 CytomX Therapeutics shares in Q3 2019, an estimated $1K.
  • San Francisco Sentry Investment Group first reported a position in CytomX Therapeutics in Q2 2019 and held it in 1 quarter.
  • San Francisco Sentry Investment Group's CytomX Therapeutics position peaked at $1K in Q2 2019.
  • 113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2019.

Based on San Francisco Sentry Investment Group's 13F filing for Q3 2019, filed 18 Oct 2019.